GSK buys asthma drug developer for up to $1.4 bn

by

British drugmaker GlaxoSmithKline on Tuesday agreed to buy Aiolos Bio for up to $1.4 billion, with focus on an asthma medication still at the testing stage.

Leave A Comment

Your email address will not be published. Required fields are marked *